The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial.
 
Chang Gon Kim
No Relationships to Disclose
 
Jin-Hee Ahn
No Relationships to Disclose
 
Jeong Eun Kim
No Relationships to Disclose
 
Jee Hung Kim
No Relationships to Disclose
 
Min Kyung Jeon
No Relationships to Disclose
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Indivumed; Ipsen; MSD Oncology
Speakers' Bureau - Eisai; Eisai; Lilly
Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Eisai; Immunomet; medpacto; MSD Oncology; Roche/Genentech; Sillajen
 
Hyo Song Kim
No Relationships to Disclose